The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1369
Roflumilast (Daliresp) for COPD
The full article is available to subscribers Subscriber Login   

Roflumilast (Daliresp – Forest), an oral phosphodiesterase 4 (PDE4) inhibitor, was approved by the FDA to reduce the risk of exacerbations in adult patients with severe chronic obstructive pulmonary disease (COPD) associated with chronic bronchitis and a history of exacerbations.

STANDARD TREATMENT — The goals of drug therapy for COPD are to reduce symptoms such as dyspnea, improve exercise tolerance and quality of life, and decrease complications of the disease such as acute exacerbations. COPD exacerbations may hasten progression of the disease and lead to early mortality.

Patients with mild, intermittent COPD symptoms can be treated with an inhaled short-acting bronchodilator for symptom relief. When symptoms become more severe or persistent, an inhaled long-acting bronchodilator may be used. Combinations of a beta2-agonist with an anticholinergic can be used for patients inadequately ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Immediate Online access to current issue and archives from 1988 to the present
  • Mobile access to our mobile site and free apps for iOS, Android and Kindle
  • FREE online per issue CME/CE
Free trial offer
3 Free Issues of The Medical Letter on Drugs and Therapeutics mailed to your home or office PLUS online access.
Try a Free Trial Subscription
Purchase this article:
Title: Roflumilast (Daliresp) for COPD
Article code: 1369b
 Electronic, downloadable article - $25